This paper describes the validation of a sensitive, accurate, and reproducible method for the determination of a release profile of glipizide from controlled-release dosage forms. In this method, an in vitro dissolution profile of commercial controlled-release dosage forms is determined using a reversed-phase C(18) column, mobile phase (acetonitrile-buffer, 0.05 M KH(2)PO(4) adjusted to pH 3.5 ...

the objective of research was to explore the suitability of lipids like compritol 888 ato and stearic acid as release retardant to develop sustained release (sr) tablets. the sr micromatrices of lipid (s) and glipizide were prepared (lm1- lm6) as intermediate product by fusion method and assessed for various pharmacotechnical properties. micromatrices were formulated as sr tablets (f1-f6) by di...

BACKGROUND Coadministration of co-trimoxazole with sulfonylureas is reported to increase the risk of hypoglycemia. METHODS We identified a cohort of Medicare beneficiaries aged 66 years or older who took glyburide or glipizide for diabetes from a 5% national sample of Medicare Part D claims data in 2008 (n = 34,239). We tracked each participant's claims during 2008-2010 for a co-trimoxazole p...

Patients with diabetic nephropathy have a high rate of cardiovascular events and mortality. Nontraditional cardiovascular risk factors such as oxidative stress and inflammation are thought to be particularly important in mediating these events. Studies suggest that thiazolidinediones (TZDs) can reduce the level of nontraditional cardiovascular risk in people with or without diabetes mellitus. W...